NCT01891747View on ClinicalTrials.gov

A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

January 31, 2022

Conditions
Malignant Glioma
Interventions
DRUG

Bevacizumab

bevacizumab at 10mg/kg IV every 14 days (Phase I \& phase II)

DRUG

Temozolomide

150 mg/m2/day for a 5-day regimen per month (Phase I \& Phase II)

DIETARY_SUPPLEMENT

Vitamin C

250 mg vitamin C once a day (oral) - Phase I \& Phase II

Trial Locations (1)

37232

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT01891747 - A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma | Biotech Hunter | Biotech Hunter